Stem cells: why that market can expand - you discover its sales potential
What are the commercial prospects for stem cells? Visiongain's updated report
predicts revenues to 2023. There you find the best places for sales growth,
also understanding trends, technologies, therapies, and opportunities.
That study gives you revenue forecasts to 2023 for the overall world market
and its submarkets. See what's happening for those cellular technologies,
finding how you can gain.
Read on to explore that industry and see what its future market could be worth.
Forecasts 2013-2023 and other analyses - find the best opportunities
Besides revenue forecasting to 2023, our new work shows recent results, growth
rates, and market shares. There you find original analysis. See research and
development (R&D) too. You also get 40 tables, 22 charts, and three interviews
with organisations in the field.
Now make your search for data on stem cells easier. You can stay ahead in
knowledge, then, benefiting your research, analysis, and decisions. Also save
Our new study lets you investigate the most promising and lucrative parts of
that field - assess technologies and their applications. You hear what's going
on and see where the money lies. Try our new report, then, getting feel for
the stem cell industry's potential.
The following sections show how you benefit from that investigation.
Prospects from 2013 for the world market and submarkets
What are the secrets of that industry's progress? Along with our prediction of
the overall world market for stem cells, our work shows you individual revenue
forecasting of five submarkets to 2023 at world level:
Central nervous system (CNS) disorders
Other therapeutic applications
See how and why those segments can prosper. That analysis helps you identify
potential for stem cell products and services. Assess how tools and systems
can make money.
There you also explore challenges and strengths of that industry and market,
helping you compete and gain advantages. You see prospects for established and
emerging technology. That market will grow through the approval and launch of
Our study explains, discussing issues to help your work.
Developments, challenges, and opportunities affecting stem cells
The report lets you assess trends and outlooks for stem cells. There, looking
ahead, you find discussions of issues and developments:
Efforts and outlooks in the US, Japan, Europe, South Korea, China, and
Regulations and ethics for stem cell research and uses in medicine
Embryonic stem cells (ESCs) and induced pluripotent adult cells (IPSCs)
Haematopoietic stem cell transplantation (HSCT)
Uses for umbilical cord blood and related technologies
Supply, storage (banking) and processing of the cellular material.
That investigation discusses other aspects of stem cell technology too,
Activities of Osiris Therapeutics, Gamida Cell, Novartis, Baxter, NeoStem,
Approvals of therapies and other products to expand and progress the sector
Orphan diseases and other under-treated conditions
Metabolic applications - diabetes and liver treatments
Agents for osteogenesis and treating autoimmune disorders
Cell-based assays - uses in diagnostic tests and devices.
There you explore political, economic, social, and technological questions,
assessing advances and outlooks for business. You also gain regulatory
insights. See, then, what stimulates and restrains organisations in that
For example, the author of the report said: "Companies are targeting ischaemic
disorders of the cardiovascular and cerebrovascular systems, in 2012 the
biggest causes of death worldwide. More than 20 stem cell products tackling
those diseases are in clinical trials."
Discover, then, what the present and future hold.
Stem cells - what 2017 market value?
What happens next? From 2013, stem cell products and services hold great
potential for investments, technological advances and sales. Our new report
predicts the world market for those technologies will reach $10.7bn in 2017,
achieving high growth from 2013 to 2023.
Prospects for those medical tools and systems are strong, and from 2013 to
2023 there will arise many opportunities. Our analyses show you the
possibilities, helping you stay ahead.
Information found nowhere else
In particular, then, our new study gives you these advantages:
Revenues to 2023 for stem cells at world level, with forecasting of five
submarkets - assess prospects for investments and sales
Interviews with other authorities - discover what participants from
industry and academia think, say, and do, helping you stay ahead
Prospects for established competitors and new entrants - explore
activities, results, R&D, and outlooks for future success.
Stem Cell Technologies: World Market Outlook 2013-2023 gives
independent analysis. There you receive business intelligence found only in
our work, finding where money lies.
With that report you are less likely to fall behind in knowledge or miss sales
opportunity. See there how you could benefit your research, analysis, and
decisions. Explore progress and possibilities. Also find how you can save time
and get recognition for insight.
Stem cells - assess commercial potentials now, seeing what you can gain
Our new report is for everyone analysing biotechnology for healthcare -
pharmaceuticals, diagnostics, and medical devices. There you find sales
predications with discussions. Avoid missing out - please order the report now.
Table of Contents
1. Executive Summary
1.1 Overview of Findings
1.2 Chapters in the Report
1.3 Research and Analysis Methods
2. Overview of the Stem Cells Market, 2013-2023
2.1 Strong Market Performance Expected 2013-2023
2.2 Cancer Segment Represents Bulk of Stem Cell Therapy Revenues, 2013
2.2.1 Other Therapeutic Areas to Gain Ground by 2023
2.2.2 Market Breakdown Focuses on Key Therapeutic Areas
2.3 Which Types of Stem Cells Matter for the Market?
2.3.1 The Discovery of Stem Cells
2.3.2 Embryonic Stem Cells (ESCs) Enter the Picture
2.3.3 Only ESCs and Induced Pluripotent Adult Cells (IPSCs) Have
2.3.4 MSCs Prominent in Clinical Trials
2.3.5 Autologous and Allogeneic Properties
2.3.6 Different Cell Advantages and Disadvantages
2.4 The Global Regulatory Environment for Stem Cells
2.4.1 US: No Morality Clause, Much Venture Capital
188.8.131.52 ESC Controversy Now Settled?
184.108.40.206 FDA Vs Regenerative Sciences
2.4.2 Japan: Liberal on hESCs
220.127.116.11 First-in-Human iPSC Trial Announced in 2013
2.4.3 Europe: No Consistent Position Across the Continent
18.104.22.168 The Brüstle Ruling: Dead and Buried?
22.214.171.124 The UK Leads in European Stem Cells R&D
2.4.4 Rest of the World
126.96.36.199 South Korea: Leading the Way in MSC Approvals
188.8.131.52 China: Liberal Laws on Stem Cell Research
184.108.40.206 Israel - Long-Term Research Activity
220.127.116.11 'Stem Cell Tourism'
3. Stem Cell Cancer Therapeutics Segment 2013-2023
3.1 HSCT Will Underpin the Growth of the Cancer Segment in the 2013-2023
3.2 Stem Cells: 45 Years as a Major Part of Blood Cancer Treatment
3.2.1 Autologous HSCT Operations Still Dominate Segment
3.2.2 Allogeneic HSCT: More Rejections, Fewer Relapses
3.2.3 GvHD: The Major Issue for HSCT
3.2.4 Peripheral Blood: More Anti-Tumour Effect, More GvHD Risk
3.2.5 The Rise of Umbilical Cord Blood
3.2.6 Around 60,000 HSCT Operations Performed Worldwide in 2012
3.2.7 HSCT Costly, Medicare Coverage Selective
3.2.8 Haematological Malignancies the Major Indication for HSCT
3.2.9 HSCT Addresses Cancers Representing a $20bn+ Market
3.2.10 From Successful Procedure to Successful Products? The Next Stage
for the HSCT Sector
3.3 Pipeline Maturing, with First Approval in 2012
3.3.1 Osiris Therapeutics - Prochymal Finally Makes it to Market
18.104.22.168 Osiris Leads the Pack in Stem Cell Therapeutics
22.214.171.124 Using MSCs for Immunosuppression
126.96.36.199 Positive Results in Acute Paediatric GvHD
188.8.131.52 An Important Role to Play in the Future of HSCT
3.3.2 The Clinical-Stage Pipeline: Two More Candidates in Phase 3
3.3.3 Gamida Cell - StemEx: The Next Stem Cell Product to Market?
184.108.40.206 Survival at 100 Days Improved by StemEx in Latest Trial
220.127.116.11 FDA Remains Unconvinced
18.104.22.168 NiCord Heads Up a Pipeline of New Cell Therapy Products
22.214.171.124 NiCord Promising So Far
3.3.4 Mesoblast - Using Mesenchymal Precursors to Enrich Cord Blood